Articles related to CARDIOVASCULAR DISEASE (CVD)

The FDA-approved LODOCO is anticipated to significantly advance cardiovascular treatment, reducing cardiac events by 31% in established cardiovascular disease patients. Read about the innovative research that has led to this breakthrough in patient care.

In the challenging landscape of managing borderline CVD risk, understanding the role and implications of a one-year-old coronary calcium score is pivotal. Dive deeper into this complex scenario to navigate patient management with precision and evidence-based insight.

Enhancing Cardiovascular Disease Risk Prediction: Comparing Coronary Artery Calcium and Polygenic Risk Scores A Northwestern University study revealed that both coronary artery calcium and polygenic risk scores significantly influence 10-year risk prediction for coronary heart disease. However, coronary artery calcium score demonstrated superior predictive power, reinforcing the integration of these novel tools in risk prediction models. “What this study says is that in white participants enrolled in 2 observational studies, identifying coronary calcium predicted future cardiac events better than our currently available polygenic risk scores.” Dr. Karol E. Watson, PhD, professor of medicine and cardiology at the David Geffen School of Medicine at the University of California Los Angeles

According to census data, there are 49.2 million older persons in the United States, with 21 million (42.6%) earning less than 200% of the federal poverty threshold. With the majority of older persons having their natural dentition, there will be an increased demand for oral health (OH) treatments among this demographic. Although the causative links between oral and systemic diseases are still developing and not entirely established, there is undeniably a bidirectional relationship between OH, cardiovascular disease, and diabetes in older persons.

Clinicians are directed to the American College of Cardiology/American Heart Association pooled cohort equation, which takes into account age, gender, blood pressure, lipids, diabetes mellitus, and tobacco use but not family history. The USPSTF now advises against starting aspirin therapy in individuals 60 and older since there is no net benefit and the risk of damage may outweigh the benefit. The USPSTF guidelines are based on evidence from 13 trials, which show that aspirin has a slight advantage for select adults aged 40 to 59, but no net benefit (with the potential for harm) for patients aged 60 and older.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?